Evidence map›Paper›PMID 28562069›Full record

ArticleAIDS research and human retroviruses2018

"We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.

Karine Dubé, David Evans, Lynda Dee, Laurie Sylla, Jeff Taylor, Asheley Skinner, Bryan J Weiner, Sandra B Greene, Stuart Rennie, Joseph D Tucker

Abstract read
In one paragraph

Article in AIDS research and human retroviruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karine Dubé1 University of North Carolina Gillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC-CH) , Chapel Hill, North Carolina.
David Evans2 Delaney AIDS Research Enterprise (DARE) Community Advisory Board (CAB) , San Francisco, California.
Lynda Dee2 Delaney AIDS Research Enterprise (DARE) Community Advisory Board (CAB) , San Francisco, California.
Laurie Sylla6 defeatHIV CAB , Seattle, Washington.
Jeff Taylor5 amfAR Institute for HIV Cure Research CAB , San Francisco, California.
Asheley Skinner1 University of North Carolina Gillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC-CH) , Chapel Hill, North Carolina.
Bryan J Weiner1 University of North Carolina Gillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC-CH) , Chapel Hill, North Carolina.
Sandra B Greene1 University of North Carolina Gillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC-CH) , Chapel Hill, North Carolina.
Stuart Rennie10 Department of Social Medicine and UNC Center for Bioethics , Chapel Hill, North Carolina.
Joseph D Tucker11 UNC Project China , Guangzhou, China .

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Cell and Gene Therapy for HIV CureUM1AI126623 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JEROME, KEITH R, KIEM, HANS-PETER · 2016 to 2020
$24.2M
Unintended and Intended Implications of HIV Cure: A Social and Ethical AnalysisR01AI108366 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RENNIE, STUART, TUCKER, JOSEPH DAVID · 2013 to 2017
$2.9M
NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI108366NIAID NIH HHS UM1 AI126623
6 · The paper itself

Abstract

Strategies to control HIV in the absence of antiretroviral therapy are needed to cure HIV. However, such strategies will require analytical treatment interruptions (ATIs) to determine their efficacy. We investigated how U.S. stakeholders involved in HIV cure research perceive ATIs. We conducted 36 in-depth interviews with three groups of stakeholders: 12 people living with HIV, 11 clinician-researchers, and 13 policy-makers/bioethicists. Qualitative data revealed several themes. First, there was little consensus on when ATIs would be ethically warranted. Second, the most frequent perceived hypothetical motivators for participating in research on ATIs were advancing science and contributing to society. Third, risks related to viral rebound were the most prevalent concerns related to ATIs. Stakeholders suggested ways to minimize the risks of ATIs in HIV cure research. Increased cooperation between scientists and local communities may be useful for minimizing risk. Further ethics research is necessary.

Indexed as

Time-to-TreatmentBiomedical ResearchFemaleHIV InfectionsHumansIntersectoral CollaborationMaleQualitative ResearchUnited StatesHIV cure researchperceptionstreatment interruptionsUnited States

Identifiers

PMID28562069
PMCPMC5771546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.